Relay Therapeutics (RLAY) President Donald A. Bergstrom Sells Shares

What Happened
Donald A. Bergstrom, President, Research & Development at Relay Therapeutics, sold 8,530 shares in an open-market transaction on September 8, 2026. The sale yielded approximately $161,814 based on a weighted-average price of $18.97 per share. The trades were executed across multiple prices ranging from $18.56 to $19.24.

Key Details

• Transaction date: 2026-09-08; Form 4 filed 2026-09-09 (timely).
• Transaction type: Open-market sale (Code S).
• Shares sold: 8,530; weighted-average price $18.97; gross proceeds ≈ $161,814.
• Price range and execution: Multiple trades at $18.56–$19.24; weighted average reported (reporting person can provide per-trade breakdown on request). (F2)
• Pre-scheduled plan: Executed pursuant to a Rule 10b5-1 trading plan adopted October 30, 2025. (F1)
• Holdings note: Filing indicates holdings include 10,025 shares underlying restricted stock units. (F3)
• Filing status: Report appears timely (filed the next day); not marked late.

Context
This was a sale under a pre-established 10b5-1 plan, which typically means the trades were pre-scheduled and may not reflect immediate insider views on the company's prospects. Sales by executives are common for liquidity or diversification; retail investors should weigh this single, modest-sized sale alongside broader insider activity and company fundamentals.